Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019
Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2 -agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020
The clinical impact of adherence to therapy in airways disease Source: Breathe, 17 (2) 210039; 10.1183/20734735.0039-2021 Year: 2021
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Do different combinations of bronchodilator therapies have different effects on health status in patients with COPD? Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011
Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012
The influence of fenspiride in complex therapy on quality of life in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020
Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018
Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Optimal adherence with inhaled corticosteroids is related to better health status Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019